In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eon Labs Inc.

Division of Novartis AG

Latest From Eon Labs Inc.

Cipla Sees Growth In Product-Based Alliances; In Deal With Teva For Inhalers In Russia

India’s second largest drug maker draws newer strategies to keep pace with emerging markets’ growth momentum, Cipla Chairman Yusuf Hamied tells PharmAsia News in an exclusive interview.

BioPharmaceutical India

KV Settles DoJ Complaint Over Claims For Unapproved Drugs; Two Dozen Companies Sued

The $17 million settlement resolves a False Claims Act suit alleging KV’s Ethex subsidiary illegally received reimbursement for two unapproved drugs; at least three other companies have previously settled with the government.

BioPharmaceutical Regulation

Can't Say No: Pharma's Addiction to Shareholder Payouts

Having created a shareholder addiction to cash payments, companies are now going to have to make the unpleasant choice between pleasing investors in the short term and building their businesses over the next decade. IN VIVO examines pipeline confidence, patent expirations, and cash flow woes to make some forecasts about the industry's financial health, as well as looking inside the strategies that Big Pharma is currently pursuing.
BioPharmaceutical Business Strategies

Novartis/Hexal: Generic Consolidation, and More

Buying Hexal shows Novartis' commitment to generics. The Swiss group also hopes the move will bring more credibility, and better deals, across all of its businesses.
BioPharmaceutical Strategy
See All

Company Information